目的 探讨不同剂量乌司他丁联合肺保护性通气对肝移植手术患者肺损伤血清生物标志物和炎性因子的影响。方法 选择2014-12至2018-04医院行原位肝移植术的终末期肝病患者60例(终末期肝病评分-MELD评分<15分),随机分为肺保护性通气组(A组),肺保护性通气+5万U/kg乌司他丁(B组)和肺保护性通气+10万U/kg乌司他丁(C组),每组20例。所有患者分别于手术开始前(T1)、无肝前期3 h (T2)、新肝期2 h(T3)及新肝期4 h (T4),检测桡动脉血气及血中肺损伤血清生物标志物,同时,经纤维支气管镜采集肺泡灌洗液(bronchoalveolar lavage fluid,BALF),检测BALF中炎性因子的水平。记录术后2 h、拔管前和术后2 d的氧合指数(PaO2/FiO2)及术后拔管时间、ICU停留时间和急性肺损伤(acute lung injury, ALI)的发生情况。结果 与A组比较,B组、C组克拉拉细胞分泌蛋白16(clara cell secretory protein,CC16)、血清表面活性蛋白(surfactant proteins,SP-D)和高级糖基化终末产物可溶性受体(soluble receptor for advanced glycation end-products ,sRAGE) 水平在T3时均较低,C组CC16水平在T2时也较低;B组BALF中仅肿瘤坏死因子-α(TNF-α)水平在T2、T4时较低,C组TNF-α水平在T2、T3、T4时,白介素-8(IL-8)水平在T3、T4时均较低;B组患者PaO2/FiO2仅在T4时较高,C组PaO2/FiO2在T2－术后2 h均较高,且平均拔管时间[(6.9±0.9)h &(6.5±1.3)h]和ICU存留时间[(1.9±0.6)d &(1.8±0.4)d]也较短,差异均有统计学意义(P<0.05)。结论 乌司他丁联合肺保护性通气能降低肝移植手术患者肺损伤血清标志物和BALF中炎性因子的水平,改善氧合指数,缩短拔管时间和ICU停留时间,较大剂量乌司他丁(10万U/kg)的保护作用更强。
Abstract
Objective To explore the effecs of different doses of ulinastatin combined with lung-protecting mechanical ventilation on acute lung injury after orthotopic liver transplantation by observing the changes of plasma markers of lung injury and inflammatory mediators.Methods Sixty patients scheduled for liver transplantation under general anesthesia received different doses of ulinastatin combined with the lung-protecting mechanical ventilation strategy. All the patients were randomly divided into three groups: patients in group A were treated with lung-protecting mechanical ventilation alone, group B in which lung-protecting mechanical ventilation was adopted combined with ulinastatin 50,000 U/kg, and group C which was combined with ulinastatin 100,000 U/kg instead. Blood samples were collected from the radial artery for blood gas results and fluid plasma markers of lung injury while bronchoalveolar lavage fluid (BALF) was collected for inflammatory mediators at the following time points: before operation(T1), 3 h in the preanhepatic stage (T2), 2 h (T3)and 4 h in the neohepatic stage (T4). Plasma markers of lung injury, which were clara cell secretory protein 16(CC16), surfactant proteins(SP-D) and soluble receptor for advanced glycation end-products (sRAGE), and inflammatory mediators such as TNF-α and IL-8, were monitored. Moreover, the oxygenation index (PaO2/FiO2,OI), time of tracheal extubation, length of ICU stay and incidence of acute lung injury within one week were recorded.Results Compared with patients in group A, levels of CC16, SP-D and sRAGE in group B and group C were all lower at T3, so was CC16 in group C at T2. In group B, levels of TNF-α at T2 and T4 were lower, so were levels of TNF-α in group C from T2 to T4 and IL-8 at T2 and T4 (P<0.05). Moreover, PaO2/FiO2 (OI) was relatively high in group B at T4, and from T2 to 2 h after operation in group C, where an earlier tracheal extubation and a shorter ICU stay were observed (P<0.05).Conclusions Ulinastatin(100,000 U/kg) combined with the lung-protecting mechanical ventilation strategy may contribute to the protection of lung function in patients for liver transplantation, which can lead to lower levels of plasma markers of lung injury and inflammatory mediators, a higher OI, earlier tracheal extubation and a shorter stay of ICU.
关键词
急性肺损伤 /
肺损伤血清生物标志物 /
肺泡灌洗液 /
炎性因子 /
肝移植 /
肺保护性通气 /
乌司他丁
Key words
acute lung injury /
plasma marker of lung injury /
bronchoalveolar lavage fluid /
inflammatory mediator /
liver transplantation /
lung-protecting mechanical ventilation strategy /
ulinastatin
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 孟稳利,刘志华,缪 洁.肝移植术后肺部感染相关因素临床分析[J].中国现代医学杂志,2013,23(22):104-106.
[2] Han S,Mallampalli P K.The role of surfactant in lung disease and host defense against pulmonary infections[J].Ann Am Thorac Soc,2015,12(5):765-774.
[3] Feng Z,Shi Q,Fan Y,et al.Ulinastatin and/or thymosin α1 for severe sepsis:a systematic review and meta-analysis [J].J Trauma Acute Care,2016,80(2):335-340.
[4] Bemard G R,Artigas A,Brigham K L,et al.The American-European consensus conference on ARDS, definitions ,mechanisms,relevant outcomes and clinical trial coordination[J].Am J Respir Crit Care Med,1994,149(3):818-824.
[5] Wright B J.Lung-protective ventilation strategies and adjunctive treatments for emergency medicine patient with acute respiratory failure[J].Emerg Med Clin North Am,2014,32(4):871-887.
[6] 董 兰,安丽娜,岳 阳,等.肺保护性通气对肝移植手术患者肺损伤血清标志物和炎性因子的影响[J].临床麻醉学杂志,2017,6(33):525-528.
[7] 李占军,张迁龙,陈晓阳,等.肺保护性通气对不同MELD分值肝移植手术患者的肺保护性作用[J].武警医学,2018,29(4):388-391.
[8] Wang L Z,Luo M Y,Zhang J S,et al.Effect of ulinastatin on serum inflammatory factors in Asian patients with acute pancreatitis before and after treatment:a meta-analysis[J].Int J Clin Pharmacol Ther,2016,54(11):890-898.
[9] 王忠慧,李珊珊,汪亚宏,等.乌司他丁对单肺通气患者血浆IL-8、IL-10及肺AQP1、AQP4的影响[J].临床麻醉学杂志,2013,29(5):421-424.
[10] Mcauley D F,Matthay M A.Clara cell protein CC16:a new lung epithelial biomarker for acute lung injury[J].Chest,2009,135(6): 1408-1410.
[11] Wutzler S,Lehnert T,Laurer H,et al.Circulating levels of Clara cell protein 16 but not surfactant protein D identify and quantify lung damage injuries[J].J Trauma,2011,71 (2): 31- 36.
[12] 闻梦妮,赵 钢,郑宪友,等.创伤早期肺特异性相关蛋白测定对识别和量化肺挫伤的价值初探[J].创伤外科杂志,2014,16(2):100-103.
[13] Shimizu Y,Sunaga N,Dobashi K,et al.Serum markers in interstitial pneumonia with and without pneumocystis jirovecii colonization:a prospective study[J].BMC Infect Dis,2009,9 (4 ):76-82.
[14] Uchida T,Shirasawa M,Ware L B,et al.Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury[J].Am J Respir Crit Care Med,2006,173(9):1008-1015.
[15] Mokra D,Kosutova P.Biomarkers in acute lung injury[J].Respir Physiol Neurobi,2015,209(14):52-58.
[16] Fagon J Y.Diagnosis and treatment of ventilator-associated pneumonia:fiberoptic bronchoscopy with beonchoalveolar lavage is essential[J]. Semin Respir Crit Care Med,2006,27(1):34-44.
基金
国家高技术研究发展计划(863计划)(2012AA021006)
PDF(749 KB)
